SCHEMBL4869856

SCHEMBL4869856

Cc1noc(C)c1S(=O)(=O)Nc1cccc(C#Cc2c(N)ncnc2N)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
PIK3CA P42336 1/20 0.45
TSHR P16473 1/20 0.44
MAPT P10636 6/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NR3C2 P08235 2/20 0.43
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 2/20 0.40
POLB P06746 2/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875769 0.78 HTR6 (0.53) ALDH1A1PIK3CAKMT2ALMNAMEN1
SCHEMBL4879656 0.75 L3MBTL1 (0.47) ALDH1A1KMT2AMEN1GAA
SCHEMBL4875782 0.74 CA12 (0.48) ALDH1A1PIK3CAMAPTKMT2APOLB
SCHEMBL4878313 0.74 SLC22A12 (0.46) PIK3CAKMT2AMEN1
SCHEMBL4876133 0.74 BRAF (0.46) ALDH1A1PIK3CAKMT2ALMNAMEN1
SCHEMBL4880842 0.74 GAA (0.52) ALDH1A1PIK3CALMNASMN1; SMN2GAA
SCHEMBL4876461 0.74 TSHR (0.45) ALDH1A1PIK3CATSHRKMT2ALMNA
SCHEMBL4878244 0.74 SGK1 (0.46) ALDH1A1KMT2ALMNAMEN1HPGD
SCHEMBL4878331 0.73 KIT (0.46) PIK3CALMNA
SCHEMBL4875699 0.73 ALDH1A1 (0.49) ALDH1A1PIK3CAMAPTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146599-A1 Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity ASTRAZENECA AB (SE) 2008-06-19 US disclosed
US-20080146599-A1 Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity ASTRAZENECA AB (SE) 2008-06-19 US disclosed
US-20080146599-A1 Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity ASTRAZENECA AB (SE) 2008-06-19 US disclosed
EP-1846399-A1 PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-10-24 EP disclosed
WO-2006082371-A1 PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146599-A1 Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity TIE1, TEK, KDR ALDH1A1 1838/4885PIK3CA 677/4885TSHR 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.